Brachytherapy
Volume 8, Issue 4 , Pages 353-360 , October 2009

Critical discussion of different dose–volume parameters for rectum and urethra in prostate brachytherapy

Received 3 September 2008 ,Revised 20 December 2008 ,Accepted 5 January 2009.

References 

  1. Crook JM, Potters L, Stock RG, et al. Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk. Brachytherapy. 2005;4:186–194
  2. Salembier C, Lavagnini P, Nickers P, et al. Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol. 2007;83:3–10
  3. Desai J, Stock RG, Stone NN, et al. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig. 1998;6:135–141
  4. Pötter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78:67–77
  5. Wachter-Gerstner N, Wachter S, Reinstadler E, et al. Bladder and rectum dose defined from MRI based treatment planning for cervix cancer brachytherapy: Comparison of dose-volume histograms for organ contours and organ wall, comparison with ICRU rectum and bladder reference point. Radiother Oncol. 2003;68:269–276
  6. Snyder KM, Stock RG, Hong SM, et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 2001;50:335–341
  7. Pouliot J, Kim Y, Lessard E, et al. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys. 2004;59:1196–1207
  8. Akimoto T, Katoh H, Kitamoto Y, et al. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys. 2006;65:364–370
  9. Pinkawa M, Gagel B, Piroth MD, et al. Changes of dose delivery distribution within the first month after permanent interstitial brachytherapy for prostate cancer. Strahlenther Onkol. 2006;182:525–530
  10. Zelefsky MJ, Yamada Y, Marion C, et al. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:956–963
  11. Kovacs G, Potter R, Loch T, et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol. 2005;74:137–148
  12. Kirisits C, Siebert FA, Baltas D, et al. Accuracy of volume and DVH parameters determined with different brachytherapy treatment planning systems. Radiother Oncol. 2007;84:290–297
  13. Butler WM, Merrick GS, Dorsey AT, et al. Comparison of dose length, area, and volume histograms as quantifiers of urethral dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;48:1575–1582
  14. Merrick GS, Butler WM, Wallner KE, et al. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis. Brachytherapy. 2005;4:241–251
  15. Merrick GS, Butler WM, Tollenaar BG, et al. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys. 2002;52:461–468
  16. Stock RG, Stone NN. Importance of post-implant dosimetry in permanent prostate brachytherapy. Eur Urol. 2002;41:434–439
  17. Stock RG, Stone NN, Lo YC, et al. Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys. 2000;48:899–906
  18. Bucci J, Spadinger I, Hilts M, et al. Urethral and periurethral dosimetry in prostate brachytherapy: is there a convenient surrogate?. Int J Radiat Oncol Biol Phys. 2002;54:1235–1242
  19. Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys. 2001;49:61–69

PII: S1538-4721(09)00198-6

doi: 10.1016/j.brachy.2009.01.003

Brachytherapy
Volume 8, Issue 4 , Pages 353-360 , October 2009

Article Tools

* Image Usage & Resolution